Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

Clinical and Translational Science

Volumn 10, Issue 6, 2017, Pages 443-454

  Gonzalez, Daniel ^a   Rao, Gauri G ^a   Bailey, Stacy C ^a   Brouwer, Kim L R ^a   Cao, Yanguang ^a   Crona, Daniel J ^a,b   Kashuba, Angela D M ^a   Lee, Craig R ^a   Morbitzer, Kathryn ^a   Patterson, J Herbert ^a   Wiltshire, Tim ^a   Easter, Jon ^a   Savage, Scott W ^a,b   Powell, J Robert ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BUSULFAN; CYCLOSPORIN; DIGOXIN; EDOXABAN; EFAVIRENZ; EVEROLIMUS; GENTAMICIN; PALBOCICLIB; POLYMYXIN B; RAPAMYCIN; RIVAROXABAN; TACROLIMUS; TEMSIROLIMUS; TOBRAMYCIN; VENETOCLAX; WARFARIN;

DRUG DOSE; ELECTRONIC HEALTH RECORD; FOOD AND DRUG ADMINISTRATION; HEALTH CARE NEED; HUMAN; NONHUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRECISION DOSING; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; UNITED STATES; DOSE RESPONSE; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PATIENT CARE; PRECISION MEDICINE; PUBLIC HEALTH; TREATMENT OUTCOME;

EID: 85032922602     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12490     Document Type: Review

References (100)

1. Henry, J., Pylypchuk, Y., Searcy, T. & Patel, V. Adoption of Electronic Health Record Systems among U.S. Non-Federal Acute Care Hospitals: 2008–2015. May 2016. Accessed via: . Accessed on June 21, 2017.
2. Darwich, A.S. et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin. Pharmacol. Ther. 101, 646–656 (2017).
3. Neely, M. Scalpels not hammers: The way forward for precision drug prescription. Clin. Pharmacol. Ther. 101, 368–372 (2017).
4. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015).
5. Pacanowski, M., Leptak, C. & Zineh, I. Next-generation medicines: past regulatory experience and considerations for the future. Clin. Pharmacol. Ther. 95, 247–249 (2014).
6. Goodsaid, F.M. et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat. Rev. Drug Discov. 9, 435–445 (2010).
7. Gobburu, J.V.S. & Lesko, L.J. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49, 291–301 (2009).
8. Zineh, I. & Woodcock, J. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin. Pharmacol. Ther. 93, 515–525 (2013).
9. Lee, J.Y. et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 50, 627–635 (2011).
10. Genzyme Corporation. Cerdelga® package insert. August 2014. Accessed via: . Accessed on April 30, 2017.
11. Eichler, H.G. et al. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10, 495–506 (2011).
12. Huang, S.-M. et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48, 662–670 (2008).
13. Mulugeta, Y. et al. Exposure matching for extrapolation of efficacy in pediatric drug development. J. Clin. Pharmacol. 56, 1326–1334 (2016).
14. Huang, S.-M., Temple, R., Xiao, S., Zhang, L. & Lesko, L.J. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin. Pharmacol. Ther. 86, 475–479 (2009).
15. Chang, Y., Burckart, G.J., Lesko, L.J. & Dowling, T.C. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels. J. Clin. Pharmacol. 53, 962–966 (2013).
16. Johnson, J.A. & Bootman, J.L. Drug-related morbidity and mortality. A cost-of-illness model. Arch. Intern. Med. 155, 1949–1956 (1995).
17. Classen, D.C., Pestotnik, S.L., Evans, R.S., Lloyd, J.F. & Burke, J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301–306 (1997).
18. Lazarou, J., Pomeranz, B.H. & Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279, 1200–1205 (1998).
19. IMS Institute for Healthcare Informatics. Avoidable costs in U.S. healthcare. June 2013. Accessed via: . Accessed on May 13, 2017.
20. Personalized Medicine Coalition. Paying for Personalized Medicine - How Alternative Payment Models Could Help Or Hinder The Field. Accessed via: . Accessed on February 8, 2017.
21. Neely, M. et al. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob. Agents Chemother. 59, 3090–3097 (2015).
22. Neely, M. et al. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. Ther. Drug Monit. 38, 332–342 (2016).
23. Krekels, E.H.J. et al. Evidence-based morphine dosing for postoperative neonates and infants. Clin. Pharmacokinet. 53, 553–563 (2014).
24. Marsousi, N. et al. Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin. Pharmacol. Ther. 100, 295–304 (2016).
25. Evans, W.E., Relling, M.V., Rodman, J.H., Crom, W.R., Boyett, J.M. & Pui, C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338, 499–505 (1998).
26. Leroux, S. et al. Clinical utility and safety of a model-based patient-tailored dose regimen of vancomycin in neonates. Antimicrob. Agents Chemother. 60, 2039–2042 (2016).
27. Mccune, J.S. et al. Personalized dosing of cyclophosphamide in the total body irradiation – cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin. Pharmacol. Ther. 85, 615–622 (2009).
28. Sacks, L.V., Shamsuddin, H.H., Yasinskaya, Y.I., Bouri, K., Lanthier, M.L. & Sherman, R.E. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA 311, 378–384 (2014).
29. Peck, C.C. et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51, 465–473 (1992).
30. HiMSS. Electronic Health Records: A Global Perspective. Part I. August 2010. Accessed via: . Accessed on February 4, 2017.
31. Blumenthal, D. Launching HITECH. N. Engl. J. Med. 362, 382–385 (2010).
32. Gold, M. & McLaughlin, C. Assessing HITECH implementation and lessons: 5 years later. Milbank Q. 94, 654–687 (2016).
33. Centers for Disease Control and Prevention. Use and Characteristics of Electronic Health Record Systems Among Office-Based Physician Practices: United States, 2001–2013. Page last updated January 17, 2014. Accessed via: . Accessed on February 8, 2017.
34. Wojciechowski, J., Upton, R.N., Mould, D.R., Wiese, M.D. & Foster, D.J.R. Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies. AAPS J. 19, 1136–1147 (2017).
35. Hope, W.W. et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob. Agents Chemother. 57, 1888–1894 (2013).
36. Hennig, S., Holthouse, F. & Staatz, C.E. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Clin. Pharmacokinet. 54, 409–421 (2015).
37. Abdel-Rahman, S.M. et al. Design and testing of an EHR-integrated, busulfan pharmacokinetic decision support tool for the point-of-care clinician. Front. Pharmacol. 7, 1–12 (2016).
38. Barrett, J.S. Pediatric models in motion: requirements for model-based decision support at the bedside. Br. J. Clin. Pharmacol. 79, 85–96 (2015).
39. McCune, J.S. et al. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin. Cancer Res. 20, 754–763 (2014).
40. HealthIT.gov. How to Attain Meaningful Use. January 2013. Accessed via: . Accessed on January 7, 2017.
41. Touw, D.J., Neef, C., Thomson, A.H. & Vinks, A.A.; Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther. Drug Monit. 27, 10–17 (2005).
42. Tamargo, J., Heuzey, J.-Y. Le & Mabo, P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur. J. Clin. Pharmacol. 71, 549–567 (2015).
43. Kinch, M.S., Merkel, J. & Umlauf, S. Trends in pharmaceutical targeting of clinical indications: 1930–2013. Drug Discov. Today 19, 1682–1685 (2014).
44. Drusano, G.L., Ambrose, P.G., Bhavnani, S.M., Bertino, J.S., Nafziger, A.N. & Louie, A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45, 753–760 (2007).
45. Gao, B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M. & Gurney, H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol. 30, 4017–4025 (2012).
46. Mould, D.R. Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this? Clin. Pharmacol. Ther. 99, 351–354 (2016).
47. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. & Kauffman, R.E. Developmental pharmacology — drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157–1167 (2003).
48. Schwartz, J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharmacol. Ther. 82, 87–96 (2007).
49. Collins, D.C., Sundar, R., Lim, J.S.J. & Yap, T.A. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends Pharmacol. Sci. 38, 25–40 (2017).
50. Blumenthal, G.M., Mansfield, E. & Pazdur, R. Next-generation sequencing in oncology in the era of precision medicine. JAMA Oncol. 2, 13–4 (2016).
51. Preissner, S.C., Hoffmann, M.F., Preissner, R., Dunkel, M., Gewiess, A. & Preissner, S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8, e82562 (2013).
52. Haider, S. & Pal, R. Integrated analysis of transcriptomic and proteomic data. Curr. Genomics 14, 91–110 (2013).
53. Chapal, N., Molina, L., Molina, F., Laplanche, M., Pau, B. & Petit, P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: Applications in diabetes and cancer. Fundam. Clin. Pharmacol. 18, 413–422 (2004).
54. Witzmann, F.A. & Grant, R.A. Pharmacoproteomics in drug development. Pharmacogenomics J. 3, 69–76 (2003).
55. Kaddurah-Daouk, R. & Weinshilboum, R.M.; Pharmacometabolomics Research Network. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin. Pharmacol. Ther. 95, 154–167 (2014).
56. Beumer, J.H. Without therapeutic drug monitoring, there is no personalized cancer care. Clin. Pharmacol. Ther. 93, 228–230 (2013).
57. Sheiner, L.B. & Ludden, T.M. Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 32, 185–209 (1992).
58. Sheiner, L.B. & Steimer, J.L. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. 40, 67–95 (2000).
59. Jones, H.M. et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin. Pharmacol. Ther. 97, 247–262 (2015).
60. Sheiner, L.B. & Beal, S.L. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 71, 1344–1348 (1982).
61. Kiang, T.K.L., Sherwin, C.M.T., Spigarelli, M.G. & Ensom, M.H.H. Fundamentals of population pharmacokinetic modelling: modelling and software. Clin. Pharmacokinet. 51, 515–525 (2012).
62. Jones, H. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
63. Jönsson, S. & Karlsson, M.O. A rational approach for selection of optimal covariate-based dosing strategies. Clin. Pharmacol. Ther. 73, 7–19 (2003).
64. Neely, M. & Jelliffe, R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J. Clin. Pharmacol. 50, 842–847 (2010).
65. Fukudo, M. et al. Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. J. Clin. Pharmacol. 49, 789–797 (2009).
66. Mould, D.R., D'Haens, G. & Upton, R.N. Clinical decision support tools: the evolution of a revolution. Clin. Pharmacol. Ther. 99, 405–418 (2016).
67. Mould, D.R. & Dubinsky, M.C. Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J. Clin. Pharmacol. 55 Suppl 3, S51–S59 (2015).
68. Barrett, J.S., Della Casa Alberighi, O., Läer, S. & Meibohm, B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin. Pharmacol. Ther. 92, 40–49 (2012).
69. Schlender, J.-F. et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin. Pharmacokinet. 55, 1573–1589 (2016).
70. Jadhav, P.R. et al. A proposal for scientific framework enabling specific population drug dosing recommendations. J. Clin. Pharmacol. 55, 1073–1078 (2015).
71. Younis, I.R. et al. Utility of model-based approaches for informing dosing recommendations in specific populations: report from the public AAPS Workshop. J. Clin. Pharmacol. 57, 105–109 (2017).
72. PhRMA Foundation. Principles for Responsible Clinical Trial Data Sharing. July 2013. Accessed via: . Accessed on April 29, 2017.
73. Gonzalez, D. et al. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents. Clin. Pharmacol. Ther. 96, 429–437 (2014).
74. Behrman, R.E., Benner, J.S., Brown, J.S., McClellan, M., Woodcock, J. & Platt, R. Developing the Sentinel System–a national resource for evidence development. N. Engl. J. Med. 364, 498–499 (2011).
75. Kesselheim, A.S., Cresswell, K., Phansalkar, S., Bates, D.W. & Sheikh, A. Clinical decision support systems could be modified to reduce ‘alert fatigue’ while still minimizing the risk of litigation. Health Aff (Millwood). 30, 2310–2317 (2011).
76. Yang, Y.T. & Silverman, R.D. Mobile health applications: the patchwork of legal and liability issues suggests strategies to improve oversight. Health Aff (Millwood). 33, 222–227 (2014).
77. Bearden, D.T. & Rodvold, K.A. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin. Pharmacokinet. 38, 415–426 (2000).
78. Gilbert, B., Robbins, P., Livornese, L.L. Jr. Use of antibacterial agents in renal failure. Infect. Dis. Clin. North Am. 23, 899–924 (2009).
79. Germovsek, E. et al. Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants. Antimicrob. Agents Chemother. 60, 4869–4877 (2016).
80. Smith, T.W. & Haber, E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J. Clin. Invest. 49, 2377–2386 (1970).
81. Tesfaye, H. et al. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children. Ann. Transplant. 19, 214–224 (2014).
82. Fahr, A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24, 472–495 (1993).
83. Staatz, C.E. & Tett, S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43, 623–653 (2004).
84. Johnson, J.A. et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625–629 (2011).
85. Masimirembwa, C., Dandara, C. & Leutscher, P.D.C. Rolling out efavirenz for HIV precision medicine in Africa: Are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects? OMICS. 20, 575–580 (2016).
86. Schackman, B.R., Haas, D.W., Park, S.S., Li, X.C. & Freedberg, K.A. Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics 16, 2007–2018 (2015).
87. Gatanaga, H. et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45, 1230–1237 (2007).
88. Shipkova, M. et al. Therapeutic drug monitoring of everolimus: a consensus report. Ther. Drug Monit. 38, 143–169 (2016).
89. Stenton, S.B., Partovi, N. & Ensom, M.H.H. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin. Pharmacokinet. 44, 769–786 (2005).
90. Onufrak, N.J. et al. Critical need for clarity in polymyxin B dosing. Antimicrob. Agents Chemother. 61, 1–2 (2017).
91. Baldin, B. et al. Abstract 11598: Is therapeutic drug monitoring of direct anticoagulants really unnecessary? Circulation 132, A11598 (2015). Accessed via: . Accessed on January 16, 2017.
92. Hellwig, T. & Gulseth, M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann. Pharmacother. 47, 1478–1487 (2013).
93. Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H. & Ageno, W. Measuring oral direct inhibitors of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 11, 756–760 (2013).
94. Parasrampuria, D.A. & Truitt, K.E. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin. Pharmacokinet. 55, 641–655 (2016).
95. Tamura, K. et al. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci. 107, 755–763 (2016).
96. Yi, Y., Loi, C.-M., Hoffman, J. & Wang, D. Physiologically based pharmacokinetic modeling of palbociclib. J. Clin. Pharmacol. 57, 173–184 (2016).
97. Freise, K.J. et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Pharmacokinet. 56, 515–523 (2017).
98. Freise, K.J., Shebley, M. & Salem, A.H. Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model. J. Clin. Pharmacol. 57, 796–804 (2017).
99. Jones, A.K., Freise, K.J., Agarwal, S.K., Humerickhouse, R.A., Wong, S.L. & Salem, A.H. Clinical predictors of venetoclax pharmacokinetics in chronic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 18, 1192–1202 (2016).
100. Salem, A.H., Agarwal, S.K., Dunbar, M., Enschede, S.L., Humerickhouse, R.A. & Wong, S.L. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin's lymphoma. J. Clin. Pharmacol. 57, 484–492 (2017).